T cell response against SARS-CoV-2 persists after one year in patients surviving severe COVID-19.

Background: In critically ill COVID-19 patients, the initial response to SARS-CoV-2 infection is characterized by major immune dysfunctions. The capacity of these severe patients to mount a robust and persistent SARS-CoV-2 specific T cell response despite the presence of severe immune alterations during the ICU stay is unknown.

Methods: Critically ill COVID-19 patients were sampled five times during the ICU stay and 9 and 13 months afterwards.

Monocyte CD169 expression in COVID-19 patients upon intensive care unit admission.

During the second surge of COVID-19 in France (fall 2020), we assessed the expression of monocyte CD169 (i.e., Siglec-1, one of the numerous IFN-stimulated genes) upon admission to intensive care units of 45 patients with RT-PCR-confirmed SARS-CoV2 pulmonary infection.